Congressional Affairs | DEA.gov
Pasar al contenido principal
U.S. flag

Un sitio oficial del Gobierno de Estados Unidos

Así es como usted puede verificarlo

Dot gov
Los sitios web oficiales usan .gov
Un sitio web .gov pertenece a una organización oficial del Gobierno de Estados Unidos.
Https

Los sitios web seguros .gov usan HTTPS
Un candado ( Candado Un candado cerrado ) o https:// significa que usted se conectó de forma segura a un sitio web .gov. Comparta información sensible sólo en sitios web oficiales y seguros.

  • Quiénes somos
    • Sobre la DEA
    • Mission
    • Leadership
    • Nuestra historia
    • Divisiones Nacionales
      • Operational Divisions
    • DEA Museum
    • Wall of Honor
    • Contáctenos
      • Submit a Tip
      • Extortion Scam
      • Public Affairs
      • Social Media Directory
  • Recursos
    • Cartels
    • Illegal Online Pharmacies
    • OD Justice
    • Fentanyl Supply Chain
    • Pill Press Resources
    • Recovery Resources
    • Together for Families
    • Ley de Libertad de Información
      • Fee Waiver
    • Publications
    • Galerías Multimedia
    • Programa de Asistencia a Testigos para Víctimas
      • Human Trafficking Prevention

United States Drug Enforcement Administration

  • Recibir Actualizaciones
  • Scam Alert
  • Menú Completo
  • English
  • Español

Main Menu

Explore DEA
  • Quiénes somos
    • Sobre la DEA
    • Mission
    • Leadership
    • Nuestra historia
    • Divisiones Nacionales
    • DEA Museum
    • Wall of Honor
    • Contáctenos
  • Recursos
    • Cartels
    • Illegal Online Pharmacies
    • OD Justice
    • Fentanyl Supply Chain
    • Pill Press Resources
    • Recovery Resources
    • Together for Families
    • Ley de Libertad de Información
    • Publications
    • Galerías Multimedia
    • Programa de Asistencia a Testigos para Víctimas

Congressional Affairs

Sobrescribir enlaces de ayuda a la navegación

  • Inicio
  • Congressional Affairs

Congressional Affairs

This webpage is a comprehensive, easy-to-navigate platform to enhance your understanding of DEA operations and to facilitate an ongoing collaboration with members of Congress and their staffs.

Maduro- Captured

Joint Statement from DOJ, FBI, and DEA on Bringing Nicolás Maduro into U.S. Custody to Face Justice

Read Joint Statement

DEA Extends Telemedicine Flexibilities to Ensure Continued Access to Care

New Rules Expand Telehealth Options for Opioid Use Disorder and Veterans’ Treatments

WASHINGTON – The U.S. Drug Enforcement Administration, in partnership with the Department of Health and Human Services (HHS), has issued a Fourth Temporary Extension of the COVID-19 Telemedicine Flexibilities for the Prescription of Controlled Medications, extending the current telemedicine flexibilities through December 31, 2026.

Read More

Fentanyl
* 2 mg of fentanyl equates to a potentially deadly dose

DEA Fentanyl Seizures in 2026

In 2025, DEA seized more than 47 million fentanyl-laced counterfeit pills and nearly 10,000 pounds of fentanyl powder. The 2025 seizures are equivalent to more than 369 million lethal doses of fentanyl.

The 2026 fentanyl seizures represent over 2.3 million deadly doses. *

updated: January 15, 2026
Fentanyl Pills Seized
+ 239300
Pounds of Fentanyl Powder Seized
+ lbs. 94
* 2 mg of fentanyl equates to a potentially deadly dose

Intelligence Products

Fentanyl Supply Chain

Pill Press Resources

One Pill Can Kill

Press Releases

Recovery Resources

Xylazine Information

Video Gallery

Drug Shortages/Stimulants

DEA and FDA Issue Joint Letter to the Public on Actions to Address Shortages in Prescription Stimulants

Update on the Prescription Stimulant Shortage (dea.gov)

Diversion Control Division | Stimulants (usdoj.gov)

Diversion Control Division | Quotas - 2023 Aggregate Production Quota for Methylphenidate (usdoj.gov)

DEA_Letter_to_Manufacturers.pdf (usdoj.gov)

 

Statements for the Record

February 1, 2023 - Statement of Associate Administrator Jon DeLena - Lives Worth Living: Addressing the Fentanyl Crisis, Protecting Critical Lifelines, and Combatting Discrimination Against Those with Disabilities 

February 15, 2023 - Statement of Administrator Anne Milgram - Countering Illicit Fentanyl Trafficking

April 27, 2023 - Statement of Administrator Anne Milgram - Fiscal Year 2024 Request for the Drug Enforcement Administration

May 10, 2023 - Statement of Administrator Anne Milgram - A Review of the President’s Fiscal Year 2024 Funding Requests for the Federal Bureau of Investigation and for the U.S. Drug Enforcement Administration

June 21, 2023 - Statement of Matthew J. Strait Deputy Assistant Administrator Diversion Control Division - Responding to America's Overdose Crisis: An Examination of Legislation to Build Upon the SUPPORT Act

July 12, 2023 - Statement of Kemp L. Chester Senior Advisor, Office of National Drug Control Policy Committee on Homeland Security - Leading the Strategic Response to Disrupt the Flow of Illicit Fentanyl Across Our Borders

July 27, 2023 - Statement of Administrator Anne Milgram - Drug Enforcement Administration Oversight

October 24, 2023 - Statement of William F. Kimbell Chief of Operations Drug Enforcement Administration - Hearing Entitled, “TBD”

March 20, 2024 - Testimony of James Dunlap Deputy Under Secretary for Analysis Office of Intelligence and Analysis U.S. Department of Homeland Security - Examining the Current Status of Iran’s Axis of Resistance and the Implications for Homeland Security and U.S. Interests

April 30, 2024 - Statement of William F. Kimbell Chief of Operations Drug Enforcement Administration - Hearing Entitled, “TBD”

May 7, 2024 - Statement of Administrator Anne Milgram - Fiscal Year 2025 Request for the Drug Enforcement Administration

Publications

National Drug Threat Assessment 2024
The Growing Threat of Xylazine and its Mixture with Illicit Drugs (dea.gov)

Performance Budget

DEA FY 2025 Narrative

2024 | 2023 | 2022 | 2021

Contact Us

CongressionalAffairs@dea.gov

  • Quienes Somos
    • Sobre
    • Contáctenos
    • Museo DEA
  • Recursos
    • Ley de Libertad de Información (FOIA)
    • Publicaciones
    • Galerías Multimedia
    • Programa de Asistencia a Testigos para Víctimas
  • Políticas
    • Accesibilidad, Complementos y Política
    • Políticas Legales y Descargos de Responsabilidad
    • Antidiscriminación y Represalias Acto
    • Política de Privacidad
    • Política de Igualdad de Oportunidades en el Empleo del U.S. DOJ
    • USA.gov
    • Protección de Denunciantes
    • Your Rights as a Federal Employee

United States Drug Enforcement Administration

DEA.gov is an official site of the U.S. Department of Justice
Facebook X LinkedIn Instagram

DEA Contact Center

(202) 307-1000
Contact the Webmaster